https://biopharmsignal.com/news/ACST/grace-therapeutics-provides-regulatory-update-on-new-drug-application-for-gtx-104 2026-04-23 https://biopharmsignal.com/news/REGN/otarmenitm-lunsotogene-parvec-cwha-approved-by-fda-as-first-and-only-gene-therapy-for-genetic-hearing-loss-regeneron-to-provide-otarmeni-for-free-in-the-u-s 2026-04-23 https://biopharmsignal.com/news/VIRI/dogwood-therapeutics-announces-worldwide-development-and-commercialization-partnership-for-anti-viral-assets-with-potential-value-up-to-100m 2026-04-23 https://biopharmsignal.com/news/RNXT/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamptm-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting 2026-04-23 https://biopharmsignal.com/news/DCTH/delcath-systems-to-host-first-quarter-2026-earnings-call 2026-04-23 https://biopharmsignal.com/news/LUCD/lucid-diagnostics-announces-18-million-underwritten-offering-of-common-stock 2026-04-23 https://biopharmsignal.com/news/INGN/inogen-to-report-first-quarter-2026-financial-results-on-may-7-2026 2026-04-23 https://biopharmsignal.com/news/PTIX/protagenic-therapeutics-appoints-industry-veteran-bill-nichols-jr-as-president-to-accelerate-advancement-of-first-in-class-tcap-pathway-therapy-pt00114 2026-04-23 https://biopharmsignal.com/news/HRMY/harmony-biosciences-to-report-first-quarter-2026-financial-results-on-may-7-2026 2026-04-23 https://biopharmsignal.com/news/ESPR/esperion-to-report-first-quarter-2026-financial-results-on-may-7 2026-04-23 https://biopharmsignal.com/news/CCRN/cross-country-appoints-darrick-sogabe-as-chief-product-officer-advancing-the-company-s-growing-technology-portfolio 2026-04-23 https://biopharmsignal.com/news/PSTV/plus-therapeutics-initiates-manufacturing-activities-with-spectronrx-under-a-master-services-agreement-to-support-gmp-pivotal-trial-readiness-for-reyobiqtm 2026-04-23 https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors 2026-04-23 https://biopharmsignal.com/news/XERS/xeris-biopharma-to-report-first-quarter-2026-financial-results-on-may-7-2026 2026-04-23 https://biopharmsignal.com/news/IRWD/ironwood-pharmaceuticals-to-share-real-world-hcp-perspectives-on-burden-of-total-parenteral-nutrition-in-short-bowel-syndrome-sbs-at-digestive-disease-weekr-2026 2026-04-23 https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-presents-updates-on-preclinical-immuno-oncology-programs-at-the-american-association-for-cancer-research-aacr-annual-meeting-2026 2026-04-23 https://biopharmsignal.com/news/GNTA/genenta-signs-definitive-agreements-with-sophia-high-tech 2026-04-23 https://biopharmsignal.com/news/INSM/insmed-to-host-first-quarter-2026-financial-results-conference-call-on-thursday-may-7-2026 2026-04-23 https://biopharmsignal.com/news/AVAH/aveanna-announces-first-quarter-2026-earnings-release-date-and-conference-call 2026-04-23 https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-announces-acceptance-of-abstract-at-asco-2026 2026-04-23 https://biopharmsignal.com/news/MTLS/materialise-nv-to-report-first-quarter-2026-earnings-on-thursday-may-7-2026 2026-04-23 https://biopharmsignal.com/news/USNA/usana-malaysia-launches-new-vitamin-d-supplement-with-record-breaking-jogging-event-earning-malaysia-book-of-records-title 2026-04-22 https://biopharmsignal.com/news/REGN/dupixentr-dupilumab-approved-in-the-u-s-as-the-first-biologic-medicine-for-young-children-with-uncontrolled-chronic-spontaneous-urticaria-csu 2026-04-22 https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-announces-receipt-of-nasdaq-notice-regarding-late-form-10-k-filing 2026-04-22 https://biopharmsignal.com/news/SGHT/sight-sciences-announces-the-release-of-its-sustainability-report 2026-04-22 https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-first-quarter-2026-on-april-29-2026 2026-04-22 https://biopharmsignal.com/news/EHC/encompass-health-and-cookeville-regional-medical-center-announce-plans-to-build-a-40-bed-inpatient-rehabilitation-hospital-in-cookeville-tennessee 2026-04-22 https://biopharmsignal.com/news/PSTV/plus-therapeutics-reports-granting-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4 2026-04-22 https://biopharmsignal.com/news/MEDP/medpace-holdings-inc-reports-first-quarter-2026-results 2026-04-22 https://biopharmsignal.com/news/MOH/molina-healthcare-reports-first-quarter-2026-financial-results 2026-04-22 https://biopharmsignal.com/news/SUPN/supernus-pharmaceuticals-to-announce-first-quarter-2026-financial-results-and-host-conference-call-on-may-5-2026 2026-04-22 https://biopharmsignal.com/news/BTMD/biote-schedules-first-quarter-2026-financial-results-release-and-conference-call 2026-04-22 https://biopharmsignal.com/news/OSUR/orasure-to-announce-first-quarter-2026-financial-results-and-host-earnings-call-on-may-6th 2026-04-22 https://biopharmsignal.com/news/RXST/rxsight-inc-to-report-first-quarter-2026-financial-results-on-may-6 2026-04-22 https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-presents-new-two-year-crenessityr-crinecerfont-data-showing-sustained-glucocorticoid-dose-reductions-while-maintaining-androgen-control-in-adults-with-classic-congenital-adrenal-hyperplasia 2026-04-22 https://biopharmsignal.com/news/AXON/axon-to-release-first-quarter-2026-earnings-on-may-6-2026 2026-04-22 https://biopharmsignal.com/news/CLPT/clearpoint-neuro-announces-fda-clearance-of-the-velocity-alpha-r-mr-high-speed-surgical-drill-system-and-first-clinical-use-further-expanding-our-drug-delivery-ecosystem-and-global-footprint 2026-04-22 https://biopharmsignal.com/news/FLGT/fulgent-selected-to-present-rapid-oral-abstract-within-the-head-and-neck-cancer-track-session-at-the-2026-asco-annual-meeting 2026-04-22 https://biopharmsignal.com/news/LFVN/lifevantage-to-announce-third-quarter-fiscal-year-2026-results-on-may-6-2026 2026-04-22 https://biopharmsignal.com/news/XBIO/xenetic-biosciences-inc-announces-abstract-acceptance-for-presentation-at-the-2026-asco-annual-meeting 2026-04-22 https://biopharmsignal.com/news/CAPR/capricor-therapeutics-announces-late-breaking-presentation-of-hope-3-phase-3-results-at-the-american-academy-of-neurology-2026-annual-meeting 2026-04-22 https://biopharmsignal.com/news/PRGO/perrigo-to-release-first-quarter-2026-financial-results-on-may-6-2026 2026-04-22 https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-to-announce-first-quarter-2026-financial-results 2026-04-22 https://biopharmsignal.com/news/OTLK/outlook-therapeutics-announces-5-0-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules 2026-04-22 https://biopharmsignal.com/news/SERA/sera-prognostics-announces-conference-call-and-webcast-of-first-quarter-fiscal-year-2026-financial-results-on-may-6-2026 2026-04-22 https://biopharmsignal.com/news/PMVP/pmv-pharmaceuticals-announces-board-chair-transition 2026-04-22 https://biopharmsignal.com/news/HUMA/humacyte-appoints-jim-mercadante-as-chief-commercial-officer 2026-04-22 https://biopharmsignal.com/news/MDXG/mimedx-to-host-first-quarter-2026-operating-and-financial-results-conference-call-on-april-29 2026-04-22 https://biopharmsignal.com/news/ARQT/arcutis-zoryver-roflumilast-cream-receives-strong-recommendation-in-american-academy-of-dermatology-first-ever-pediatric-atopic-dermatitis-guidelines 2026-04-22 https://biopharmsignal.com/news/PTCT/ptc-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-7-2026 2026-04-22 https://biopharmsignal.com/news/BRLI/opko-health-s-modex-therapeutics-begins-clinical-trial-of-tetraspecific-antibody-for-treatment-of-b-cell-lymphomas 2026-04-22 https://biopharmsignal.com/news/TPST/tempest-announces-key-manufacturing-milestone-for-tpst-2003-dual-targeting-cd19-bcma-car-t 2026-04-22 https://biopharmsignal.com/news/BFRG/bullfrog-ai-regains-compliance-with-nasdaq-shareholders-equity-requirement 2026-04-22 https://biopharmsignal.com/news/TGTX/tg-therapeutics-announces-data-presentations-for-briumvi-in-multiple-sclerosis-at-the-american-academy-of-neurology-2026-annual-meeting 2026-04-22 https://biopharmsignal.com/news/PRTC/puretech-reports-positive-topline-data-from-phase-1b-trial-of-lyt-200-in-relapsed-refractory-r-r-high-risk-hr-myelodysplastic-syndrome-mds-and-r-r-acute-myeloid-leukemia-aml 2026-04-22 https://biopharmsignal.com/news/SABS/sab-bio-presents-additional-clinical-and-mechanistic-data-from-sab-142-phase-1-trial-in-adult-patients-with-established-autoimmune-type-1-diabetes-at-ids-2026 2026-04-22 https://biopharmsignal.com/news/DTIL/precision-biosciences-announces-late-breaking-poster-presentation-for-pbgene-hbv-at-european-association-for-the-study-of-the-liver-congress-2026 2026-04-22 https://biopharmsignal.com/news/NRIX/nurix-therapeutics-announces-new-preclinical-data-highlighting-breadth-of-targeted-protein-degradation-pipeline-at-aacr-2026 2026-04-22 https://biopharmsignal.com/news/CERT/certara-enters-definitive-agreement-for-the-sale-of-its-regulatory-and-medical-writing-business-to-veristat 2026-04-22 https://biopharmsignal.com/news/BSX/boston-scientific-announces-results-for-first-quarter-2026 2026-04-22 https://biopharmsignal.com/news/YOU/clear-to-announce-first-quarter-2026-financial-results-on-may-6-2026 2026-04-22 https://biopharmsignal.com/news/AMRX/amneal-agrees-to-acquire-kashiv-biosciences-to-create-global-biosimilar-leader-reports-strong-preliminary-first-quarter-2026-financial-results-and-raises-fy2026-standalone-guidance 2026-04-22 https://biopharmsignal.com/news/NKTR/nektar-therapeutics-announces-pricing-of-upsized-325-million-public-offering 2026-04-22 https://biopharmsignal.com/news/FENC/fennec-pharmaceuticals-announces-acceptance-of-abstracts-at-the-2026-asco-annual-meeting 2026-04-21 https://biopharmsignal.com/news/RVMD/revolution-medicines-to-present-updated-phase-1-2-clinical-data-for-daraxonrasib-in-first-line-metastatic-pancreatic-cancer-across-monotherapy-and-combination-cohorts-at-the-2026-aacr-annual-meeting 2026-04-21 https://biopharmsignal.com/news/RVMD/revolution-medicines-to-present-preclinical-data-on-innovative-mutant-targeted-catalytic-ras-on-inhibitor-at-the-2026-aacr-annual-meeting 2026-04-21 https://biopharmsignal.com/news/EMBC/embecta-to-report-fiscal-second-quarter-financial-results 2026-04-21 https://biopharmsignal.com/news/ISRG/intuitive-announces-first-quarter-earnings 2026-04-21 https://biopharmsignal.com/news/ASND/ascendis-announces-redemption-of-all-575-million-of-outstanding-2-25-convertible-senior-notes-due-2028 2026-04-21 https://biopharmsignal.com/news/IMRX/immuneering-to-present-new-survival-data-from-first-line-pancreatic-cancer-patients-treated-with-atebimetinib-mgnp-in-an-oral-presentation-at-the-2026-asco-annual-meeting 2026-04-21 https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-presents-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-for-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting 2026-04-21 https://biopharmsignal.com/news/TELA/tela-bio-to-announce-first-quarter-2026-financial-results 2026-04-21 https://biopharmsignal.com/news/OCS/oculis-publishes-invitation-to-the-annual-general-meeting 2026-04-21 https://biopharmsignal.com/news/SGHT/sight-sciences-to-report-first-quarter-2026-financial-results-on-may-6-2026 2026-04-21 https://biopharmsignal.com/news/INBX/inhibrx-provides-clinical-update-on-ozekibart-inbrx-109-in-late-line-colorectal-cancer 2026-04-21 https://biopharmsignal.com/news/EXEL/exelixis-to-release-first-quarter-2026-financial-results-on-tuesday-may-5-2026 2026-04-21 https://biopharmsignal.com/news/ALKS/alkermes-to-report-first-quarter-financial-results-on-may-5-2026 2026-04-21 https://biopharmsignal.com/news/BRLI/opko-health-to-report-first-quarter-2026-financial-results-on-april-28-2026 2026-04-21 https://biopharmsignal.com/news/OLMA/olema-oncology-to-present-initial-clinical-data-for-op-3136-at-the-2026-asco-annual-meeting 2026-04-21 https://biopharmsignal.com/news/CORT/corcept-to-present-new-data-from-pivotal-phase-3-rosella-trial-of-lifyorlitm-relacorilant-in-patients-with-platinum-resistant-ovarian-cancer-at-asco-2026 2026-04-21 https://biopharmsignal.com/news/RVMD/revolution-medicines-to-present-pivotal-phase-3-rasolute-302-clinical-trial-results-for-daraxonrasib-in-previously-treated-metastatic-pancreatic-cancer-during-a-plenary-session-at-the-2026-asco-annual-meeting 2026-04-21 https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-announces-oral-presentation-of-silevertinib-phase-2-data-in-frontline-egfrm-nsclc-patients-at-the-2026-asco-annual-meeting 2026-04-21 https://biopharmsignal.com/news/KPTI/karyopharm-s-phase-3-sentry-trial-in-myelofibrosis-selected-for-late-breaking-oral-presentation-at-asco-2026-annual-meeting 2026-04-21 https://biopharmsignal.com/news/IRON/disc-medicine-announces-oral-presentation-of-data-from-rally-mf-phase-2-trial-of-disc-0974-in-patients-with-myelofibrosis-and-anemia-at-the-american-society-of-clinical-oncology-asco-annual-meeting 2026-04-21 https://biopharmsignal.com/news/IMTX/immatics-announces-four-upcoming-oral-presentations-across-its-clinical-cell-therapy-and-bispecific-portfolio-at-2026-asco-annual-meeting 2026-04-21 https://biopharmsignal.com/news/REGN/cemdisiran-dosed-subcutaneously-every-12-weeks-demonstrates-rapid-deep-and-sustained-disease-control-in-generalized-myasthenia-gravis-gmg-phase-3-trial 2026-04-21 https://biopharmsignal.com/news/IDYA/ideaya-biosciences-announces-late-breaking-abstract-oral-presentation-at-asco-2026-to-provide-complete-data-from-phase-2-3-registrational-trial-optimum-02-of-darovasertib-in-combination-with-crizotinib-in-1l-hla-a2-negative-metastatic-uveal-melanoma 2026-04-21 https://biopharmsignal.com/news/APRE/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting 2026-04-21 https://biopharmsignal.com/news/CLRB/cellectar-biosciences-announces-subset-of-clover-wam-clinical-trial-data-accepted-for-presentation-at-the-american-society-of-clinical-oncology-conference-2026 2026-04-21 https://biopharmsignal.com/news/HSTM/healthstream-to-host-first-quarter-2026-earnings-conference-call 2026-04-21 https://biopharmsignal.com/news/OTLK/outlook-therapeutics-completes-federal-dispute-resolution-fdr-meeting-with-fda-for-ons-5010-lytenavatm-bevacizumab-vikg 2026-04-21 https://biopharmsignal.com/news/NXGL/nexgel-new-strategic-partner-sequence-lifesciencetm-leads-financing-with-5-5-million-to-complete-acquisition-of-celularity-degenerative-disease-segment 2026-04-21 https://biopharmsignal.com/news/AVCO/avalon-quantum-ai-teams-up-with-caylent-and-amazon-web-services-on-agentic-ai-platform-development 2026-04-21 https://biopharmsignal.com/news/ICCM/icecure-participates-in-society-of-breast-imaging-symposium-2026-as-u-s-prosenser-revenue-increases-by-30-in-first-quarter-of-2026-compared-to-first-quarter-of-2025 2026-04-21 https://biopharmsignal.com/news/STIM/neuronetics-to-report-first-quarter-2026-financial-and-operating-results-and-host-conference-call 2026-04-21 https://biopharmsignal.com/news/ALLO/allogene-therapeutics-expands-pivotal-phase-2-alpha3-trial-to-south-korea-and-australia 2026-04-21 https://biopharmsignal.com/news/DERM/journey-medical-corporation-secures-contract-with-third-major-gpo-for-emrositm 2026-04-21 https://biopharmsignal.com/news/HUMA/humacyte-announces-israeli-ministry-of-health-acceptance-of-marketing-authorization-application-for-symvessr-for-vascular-trauma-repair 2026-04-21 https://biopharmsignal.com/news/TWST/twist-bioscience-to-report-fiscal-2026-second-quarter-financial-results-on-monday-may-4-2026 2026-04-21 https://biopharmsignal.com/news/COGT/cogent-biosciences-announces-oral-presentation-of-positive-phase-3-peak-trial-in-gastrointestinal-stromal-tumors-gist-at-the-2026-american-society-of-clinical-oncology-asco-annual-meeting 2026-04-21 https://biopharmsignal.com/news/CRL/charles-river-highlights-effectiveness-of-vcgs-in-toxicology 2026-04-21 https://biopharmsignal.com/news/PULM/pulmatrix-announces-closing-of-preferred-stock-transaction-as-part-of-planned-merger 2026-04-21 https://biopharmsignal.com/news/LFVN/lifevantage-receives-u-s-patent-for-healthy-glow-essentials-stack 2026-04-21 https://biopharmsignal.com/news/SHC/sotera-health-announces-first-quarter-2026-earnings-release-date 2026-04-21 https://biopharmsignal.com/news/PSTV/plus-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement 2026-04-21 https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-to-host-investor-and-analyst-meeting-on-may-14-2026-to-highlight-soquelitinib-data-being-presented-at-the-society-for-investigative-dermatology-sid-annual-meeting 2026-04-21 https://biopharmsignal.com/news/CCRN/cross-country-appoints-chris-tyrell-as-chief-information-officer-to-support-next-phase-of-enterprise-ai-and-platform-strategy 2026-04-21 https://biopharmsignal.com/news/IBRX/immunitybio-announces-anktivar-is-now-available-in-saudi-arabia-for-bladder-and-lung-cancer-patients-market-entry-achieved-within-two-months-of-mena-partnership 2026-04-21 https://biopharmsignal.com/news/MDNA/medicenna-presents-positive-data-demonstrating-superior-safety-and-efficacy-potential-of-its-first-in-class-anti-pd-1-x-il-2-bifunctional-superkine-mdna113-at-aacr-2026 2026-04-21 https://biopharmsignal.com/news/DGX/quest-diagnostics-reports-first-quarter-2026-financial-results-raises-revenue-and-eps-guidance-for-full-year-2026 2026-04-21 https://biopharmsignal.com/news/PSNL/personalis-highlights-clinical-impact-of-ultrasensitive-ctdna-monitoring-and-new-therapy-resistance-tracking-at-aacr-2026 2026-04-21 https://biopharmsignal.com/news/INBX/inhibrx-to-host-webcast-presentation-to-provide-clinical-update-on-ozekibart-inbrx-109-in-late-line-colorectal-cancer 2026-04-20 https://biopharmsignal.com/news/CVRX/cvrx-announces-nomination-of-michael-dale-for-election-to-the-board-of-directors 2026-04-20 https://biopharmsignal.com/news/JAGX/jaguar-health-reports-approval-of-all-proposals-at-april-2026-special-meeting-of-stockholders 2026-04-20 https://biopharmsignal.com/news/SIBN/si-bone-to-report-first-quarter-2026-financial-results-on-may-11-2026 2026-04-20 https://biopharmsignal.com/news/REGN/regeneron-announces-investor-conference-presentations 2026-04-20 https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-first-quarter-of-fiscal-year-2026-financial-results-on-may-4-2026 2026-04-20 https://biopharmsignal.com/news/MTLS/materialise-aandeleninkoopprogramma 2026-04-20 https://biopharmsignal.com/news/MTLS/materialise-share-buy-back-program 2026-04-20 https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-to-webcast-fiscal-2026-second-quarter-results 2026-04-20 https://biopharmsignal.com/news/NKTR/nektar-therapeutics-announces-proposed-public-offering 2026-04-20 https://biopharmsignal.com/news/CLPT/clearpoint-neuro-announces-canadian-approval-for-its-navigation-system-further-expanding-our-drug-delivery-ecosystem-and-global-footprint 2026-04-20 https://biopharmsignal.com/news/GNFT/genfit-publication-of-the-2026-extra-financial-report-fiscal-year-2025 2026-04-20 https://biopharmsignal.com/news/ANAB/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations 2026-04-20 https://biopharmsignal.com/news/OGEN/oragenics-reports-8-study-drug-doses-in-phase-iia-clinical-trial-of-onp-002-for-mild-traumatic-brain-injury 2026-04-20 https://biopharmsignal.com/news/IMRX/immuneering-presents-genetic-data-at-aacr-annual-meeting-demonstrating-mechanism-to-improve-durability-and-survival-supporting-use-of-atebimetinib-in-first-line-pancreatic-cancer-and-beyond 2026-04-20 https://biopharmsignal.com/news/GHRS/gh-research-welcomes-white-house-executive-order-to-accelerate-medical-treatments-for-serious-mental-illness 2026-04-20 https://biopharmsignal.com/news/ALLO/allogene-therapeutics-showcases-momentum-with-clinical-and-platform-advancements-in-allogeneic-car-t-at-aacr-2026 2026-04-20 https://biopharmsignal.com/news/IART/integra-lifesciences-to-host-first-quarter-2026-financial-results-conference-call-on-may-5-2026 2026-04-20 https://biopharmsignal.com/news/AMRX/amneal-announces-additional-positive-interim-phase-4-elevate-pd-results-with-crexontr-for-parkinson-s-disease-including-over-3-more-hours-of-daily-good-on-time-when-switching-from-rytaryr 2026-04-20 https://biopharmsignal.com/news/LFVN/lifevantage-inspires-with-breakthrough-announcements-at-2026-momentum-academy-in-las-vegas 2026-04-20 https://biopharmsignal.com/news/PHAT/phathom-pharmaceuticals-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-thursday-april-30-2026 2026-04-20 https://biopharmsignal.com/news/ASND/ascendis-pharma-announces-commencement-of-trading-of-its-ordinary-shares-on-nasdaq 2026-04-20 https://biopharmsignal.com/news/ARTL/artelo-announces-peer-reviewed-publication-supporting-its-fabp5-inhibitor-art26-12-as-a-novel-pain-treatment-with-a-potentially-first-in-class-profile 2026-04-20 https://biopharmsignal.com/news/NKTR/52-week-topline-results-from-16-week-blinded-treatment-extension-of-rezolve-aa-demonstrate-deepening-of-responses-in-severe-to-very-severe-alopecia-areata-with-rezpegaldesleukin 2026-04-20 https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-grant-of-rare-pediatric-disease-designation-rpdd-by-fda-to-pas-004-for-treatment-of-neurofibromatosis-type-1-nf1 2026-04-20 https://biopharmsignal.com/news/PASG/passage-bio-reports-updated-interim-data-from-uplift-d-trial-and-provides-regulatory-and-corporate-updates 2026-04-20 https://biopharmsignal.com/news/PLSE/pulse-biosciences-npulsetm-technology-to-be-featured-at-the-heart-rhythm-society-2026-annual-meeting 2026-04-20 https://biopharmsignal.com/news/MCRB/seres-therapeutics-showcases-ser-155-data-and-live-biotherapeutic-insights-at-escmid-global-2026 2026-04-20 https://biopharmsignal.com/news/MD/pediatrix-medical-group-2026-first-quarter-conference-call-webcast-scheduled-for-tuesday-may-5-2026 2026-04-20 https://biopharmsignal.com/news/PRLD/prelude-therapeutics-announces-pricing-of-90-0-million-underwritten-offering 2026-04-20 https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-presents-flamingo-01-phase-iii-trial-open-label-data-published-at-aacr-meeting-2026 2026-04-20 https://biopharmsignal.com/news/PRLD/prelude-therapeutics-presents-preclinical-data-from-development-candidate-prt13722-a-first-in-class-orally-bioavailable-potent-and-highly-selective-kat6a-degrader-at-american-association-for-cancer-research-aacr-annual-meeting-2026 2026-04-20 https://biopharmsignal.com/news/OCS/oculis-announces-completion-of-last-patient-visit-in-phase-3-diamond-program-with-ocs-01-eye-drops-for-the-treatment-of-diabetic-macular-edema 2026-04-20 https://biopharmsignal.com/news/GSK/blenrep-belantamab-mafodotin-approved-in-china-for-treatment-of-2l-relapsed-refractory-multiple-myeloma 2026-04-20 https://biopharmsignal.com/news/MNPR/monopar-presents-phase-3-data-showing-greater-neurologic-benefit-with-alxn1840-vs-soc-in-wilson-disease-patients-with-neurologic-symptoms-at-aan-2026 2026-04-19 https://biopharmsignal.com/news/IMCR/kimmtrak-doubles-the-likelihood-of-being-alive-at-five-years-for-first-line-hla-a-02-01-patients-with-metastatic-uveal-melanoma 2026-04-19 https://biopharmsignal.com/news/XENE/results-from-the-phase-3-x-tole2-study-evaluating-azetukalner-a-novel-potent-kv7-channel-opener-in-adults-with-focal-onset-seizures-fos 2026-04-19 https://biopharmsignal.com/news/XENE/treatment-experiences-with-anti-seizure-medications-asms-patient-clinician-perspectives-on-titration-burden-quality-of-life-and-no-titration-options 2026-04-19 https://biopharmsignal.com/news/XENE/xenon-presents-azetukalner-phase-3-x-tole2-study-results-and-48-month-long-term-data-in-focal-onset-seizures-at-2026-aan-annual-meeting 2026-04-19 https://biopharmsignal.com/news/RVMD/revolution-medicines-to-present-updated-phase-1-clinical-data-for-zoldonrasib-in-patients-with-previously-treated-kras-g12d-non-small-cell-lung-cancer-at-the-2026-aacr-annual-meeting 2026-04-19 https://biopharmsignal.com/news/NKTR/nektar-to-hold-conference-call-to-discuss-52-week-topline-results-from-the-16-week-extension-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-april-20-2026 2026-04-19 https://biopharmsignal.com/news/PLRX/pliant-therapeutics-announces-presentation-of-updated-data-from-the-phase-1-trial-of-pln-101095-in-patients-with-ici-refractory-solid-tumors-at-the-2026-aacr-annual-meeting 2026-04-18 https://biopharmsignal.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 2026-04-17 https://biopharmsignal.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 2026-04-17 https://biopharmsignal.com/news/SRRK/scholar-rock-reports-new-employee-inducement-grants-under-nasdaq-listing-rule-5635-c-4 2026-04-17 https://biopharmsignal.com/news/CCRN/cross-country-healthcare-to-hold-first-quarter-2026-earnings-conference-call-on-thursday-may-7-2026 2026-04-17 https://biopharmsignal.com/news/ORIC/oricr-pharmaceuticals-presents-preclinical-data-to-support-the-potential-of-rinzimetostat-across-prostate-cancer-and-in-emerging-resistance-settings-at-the-2026-american-association-for-cancer-research-aacr-annual-meeting 2026-04-17 https://biopharmsignal.com/news/ALXO/alx-oncology-reports-inducement-grant-as-permitted-by-the-nasdaq-listing-rules 2026-04-17 https://biopharmsignal.com/news/OLMA/olema-oncology-announces-preclinical-data-for-palazestrant-and-op-3136-at-the-2026-aacr-annual-meeting 2026-04-17 https://biopharmsignal.com/news/GDRX/goodrx-announces-date-for-first-quarter-2026-earnings-release-and-conference-call 2026-04-17 https://biopharmsignal.com/news/RVMD/revolution-medicines-announces-closing-of-concurrent-upsized-public-offerings-with-aggregate-gross-proceeds-of-approximately-2-2-billion-including-full-exercise-of-underwriters-option-to-purchase-additional-shares 2026-04-17 https://biopharmsignal.com/news/ACRV/acrivon-to-highlight-preclinical-data-with-three-posters-at-aacr-demonstrating-strong-acr-368-and-acr-2316-synergies-with-immune-checkpoint-inhibitors-and-adc-payloads-revealing-broad-clinical-development-opportunities 2026-04-17 https://biopharmsignal.com/news/NXGL/nexgel-moves-forward-shareholder-update-call-to-discuss-celularity-transaction-on-april-21st-at-4-30-p-m-et 2026-04-17 https://biopharmsignal.com/news/IMTX/prame-directed-cell-therapy-using-immatics-tcr-induces-deep-and-durable-remission-in-pediatric-patient-with-advanced-metastatic-nephroblastoma 2026-04-17 https://biopharmsignal.com/news/BTAI/bioxcel-therapeutics-announces-virtual-event-to-discuss-commercial-launch-plan-based-on-market-opportunity-assessment-for-igalmir-in-the-at-home-setting 2026-04-17 https://biopharmsignal.com/news/LYRA/lyra-therapeutics-inc-announces-intention-to-voluntarily-file-form-25-for-delisting-from-nasdaq-and-subsequent-deregistration-with-the-sec 2026-04-17 https://biopharmsignal.com/news/PLSE/pulse-biosciences-to-host-analyst-event-on-april-25-2026 2026-04-17 https://biopharmsignal.com/news/OSUR/orasure-technologies-appoints-john-d-bertrand-to-its-board-of-directors 2026-04-17 https://biopharmsignal.com/news/KURA/kura-oncology-reports-darlifarnib-plus-cabozantinib-demonstrates-robust-activity-in-patients-with-clear-cell-renal-cell-carcinoma-previously-treated-with-cabozantinib 2026-04-17 https://biopharmsignal.com/news/COGT/cogent-biosciences-announces-poster-presentations-at-the-american-association-for-cancer-research-aacr-annual-meeting-2026 2026-04-17 https://biopharmsignal.com/news/BRKR/bruker-expands-industry-leading-maldi-biotyperr-and-ir-biotyperr-workflows-for-microbial-identification-and-outbreak-management 2026-04-17 https://biopharmsignal.com/news/BRKR/bruker-launches-mygenius-pror-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026 2026-04-17 https://biopharmsignal.com/news/BRKR/bruker-spatial-biology-showcases-high-fidelity-spatial-data-and-integrated-multi-platform-workflows-for-unprecedented-multiomic-insights-at-aacr-2026 2026-04-17